AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12542428 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART) using hand instruments
Number of subjects: 403
Study 12542428 — intervention group
Group type: COMPARATOR
Intervention: Rotary instruments (750 r.p.m.)
Number of subjects: 403
Study 10804043 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 100 mg and 200 mg, Naproxen 500 mg twice daily
Number of subjects: 0
Study 10804043 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 0
Study 10804043 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 25 to 400 mg twice daily
Number of subjects: 0
Study 10804043 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (100 to 400 mg twice daily) and Naproxen 500 mg twice daily
Number of subjects: 0
Study 10804043 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 9115004 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 micrograms of vaginal misoprostol after 50 mg/m2 methotrexate IM
Number of subjects: 756
Study 9115004 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of vaginal misoprostol after 50 mg/m2 methotrexate IM
Number of subjects: 756
Study 9115004 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal route for second dose of misoprostol after one dose failed
Number of subjects: 756
Study 9115004 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral route for second dose of misoprostol after one dose failed
Number of subjects: 756
Study 9115004 — intervention group
Group type: COMPARATOR
Intervention: 60 mg/m2 methotrexate
Number of subjects: 756
Study 9115004 — intervention group
Group type: EXPERIMENTAL
Intervention: Three vaginal doses of misoprostol 8 hr apart starting on Day 5
Number of subjects: 756
Study 9115004 — intervention group
Group type: COMPARATOR
Intervention: One vaginal dose of misoprostol
Number of subjects: 756
Study 9115004 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall medical abortion with methotrexate and misoprostol
Number of subjects: 756
Study 8262821 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection leaving positive margins followed by postoperative adjuvant therapy (majority received postoperative radiotherapy +/- chemotherapy)
Number of subjects: 109
Study 8262821 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection leaving positive margins followed by postoperative adjuvant therapy
Number of subjects: 109
Study 8262821 — intervention group
Group type: COMPARATOR
Intervention: Definitive radiotherapy alone
Number of subjects: 109
Study 3985390 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural administration of 1.5% lidocaine with 80 mg methylprednisolone (group II)
Number of subjects: 19
Study 3985390 — intervention group
Group type: COMPARATOR
Intervention: Epidural administration of preservative-free physiologic saline solution and 80 mg methylprednisolone (group I, control group)
Number of subjects: 19
Study 31204181 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 60
Study 31204181 — intervention group
Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 60
Study 28363320 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine-naloxone with varying duration and counseling of varying intensity
Number of subjects: 653
Study 28363320 — intervention group
Group type: EXPERIMENTAL
Intervention: long-term follow-up
Number of subjects: 653
Study 28363320 — intervention group
Group type: EXPERIMENTAL
Intervention: opioid agonist treatment at the time of follow-up
Number of subjects: 653
Study 28363320 — intervention group
Group type: EXPERIMENTAL
Intervention: no agonist treatment
Number of subjects: 653
Study 25527035 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg doses, four times daily, total daily dose of 800 mg)
Number of subjects: 20
Study 25527035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23682075 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton
Number of subjects: 52
Study 23682075 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton and Celecoxib
Number of subjects: 52
Study 23682075 — intervention group
Group type: COMPARATOR
Intervention: Control (Celecoxib alone)
Number of subjects: 52
Study 21368390 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine
Number of subjects: 52
Study 21368390 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 52
Study 21368390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of carnitine and coenzyme Q10
Number of subjects: 52
Study 21368390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 19484178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumescent solution containing lidocaine and epinephrine
Number of subjects: 70
Study 19484178 — intervention group
Group type: COMPARATOR
Intervention: Tumescent solution containing only epinephrine
Number of subjects: 70
Study 17208005 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern antiemetic therapy
Number of subjects: 0
Study 17208005 — intervention group
Group type: COMPARATOR
Intervention: Control of nausea
Number of subjects: 0
Study 15200743 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (100 mg/day)
Number of subjects: 100
Study 15200743 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (150 mg/day)
Number of subjects: 100
Study 12165890 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-min vibration intervention
Number of subjects: 16
Study 12165890 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 16
Study 9822139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (with enalapril and hydrochlorothiazide if needed)
Number of subjects: 4695
Study 7640122 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 6
Study 7640122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 6
Study 2787399 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (n = 53) with occlusal interferences eliminated annually
Number of subjects: 99
Study 2787399 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 46) undergoing placebo treatment
Number of subjects: 99
Study 792853 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine anti-human-lymphocyte globulin (ALG)
Number of subjects: 0
Study 792853 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31124948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80
Study 31124948 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study 28181706 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + Fentanyl (MF group)
Number of subjects: 100
Study 28181706 — intervention group
Group type: COMPARATOR
Intervention: Propofol + Fentanyl (PF group)
Number of subjects: 100
Study 25656923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexö-method (test group24)
Number of subjects: 200
Study 25656923 — intervention group
Group type: COMPARATOR
Intervention: Control group24
Number of subjects: 200
Study 25656923 — intervention group
Group type: COMPARATOR
Intervention: External control group24
Number of subjects: 200
Study 25656923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexö-method (test group28)
Number of subjects: 200
Study 25656923 — intervention group
Group type: COMPARATOR
Intervention: Control group28
Number of subjects: 200
Study 25656923 — intervention group
Group type: COMPARATOR
Intervention: External control group28
Number of subjects: 200
Study 25656923 — intervention group
Group type: COMPARATOR
Intervention: Control groups24,28
Number of subjects: 200
Study 25656923 — intervention group
Group type: EXPERIMENTAL
Intervention: Test groups
Number of subjects: 200
Study 23547047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol-cyproteroneacetate (EE-CA)
Number of subjects: 34
Study 23547047 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combination of pioglitazone (7.5 mg/d), flutamide (62.5 mg/d), and metformin (850 mg/d) (PioFluMet)
Number of subjects: 34
Study 21334736 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-based regimen (trough concentrations 6-10 ng/mL) with enteric-coated mycophenolate sodium (1440 mg/day) and corticosteroids
Number of subjects: 503
Study 21334736 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin-based regimen
Number of subjects: 503
Study 21334736 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-based regimen
Number of subjects: 503
Study 19500829 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth-focused relationships education curriculum
Number of subjects: 0
Study 16978576 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravitreal triamcinolone acetonide
Number of subjects: 32
Study 16978576 — intervention group
Group type: COMPARATOR
Intervention: 2 mg intravitreal triamcinolone acetonide
Number of subjects: 32
Study 15106511 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 109
Study 15106511 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 109
Study 11708699 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of Nortesten (72 mg)
Number of subjects: 0
Study 11708699 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of Nortesten (144 mg)
Number of subjects: 0
Study 11708699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortesten (both doses)
Number of subjects: 0
Study 9146195 — intervention group
Group type: EXPERIMENTAL
Intervention: Oval-shaped cloth nest
Number of subjects: 102
Study 9146195 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 102
Study 8198156 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined timolol 0.5% and pilocarpine 4%
Number of subjects: 43
Study 8198156 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine 4%
Number of subjects: 43
Study 8198156 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 43
Study 3136086 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT emulsion
Number of subjects: 22
Study 3136086 — intervention group
Group type: COMPARATOR
Intervention: LCT emulsion
Number of subjects: 22
Study 3136086 — intervention group
Group type: EXPERIMENTAL
Intervention: Both emulsion types
Number of subjects: 22
Study 31619205 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined NRT (nicotine patch & gum)
Number of subjects: 560
Study 31619205 — intervention group
Group type: COMPARATOR
Intervention: Single NRT (nicotine patch)
Number of subjects: 560
Study 28189292 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (32 IE)
Number of subjects: 30
Study 28189292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25395709 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training and exercises for 3 months, 8 sessions per month, 60 to 90 minutes each session, including Hatayoga, Pranayama, and Rajayoga.
Number of subjects: 60
Study 25395709 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga training).
Number of subjects: 60
Study 22542215 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal resuscitation protocol (NRP)
Number of subjects: 0
Study 22542215 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics with facilitated referral (AFR)
Number of subjects: 0
Study 20571437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (80‐160 mg/d given twice a day, mean modal dose of 112 mg/d)
Number of subjects: 0
Study 20571437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (80‐120 mg/d given every day, mean modal dose of 96 mg/d)
Number of subjects: 0
Study 20571437 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5‐20 mg/d, mean modal dose of 12 mg/d)
Number of subjects: 0
Study 17919155 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy (n = 21)
Number of subjects: 37
Study 17919155 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 37
Study 16220454 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiochemotherapy
Number of subjects: 0
Study 16220454 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 0
Study 16220454 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy
Number of subjects: 0
Study 16220454 — intervention group
Group type: COMPARATOR
Intervention: Preoperative and postoperative radiotherapy
Number of subjects: 0
Study 16220454 — intervention group
Group type: COMPARATOR
Intervention: Preoperative and postoperative chemotherapy
Number of subjects: 0
Study 12149204 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Methotrexate (LDMTX: 6 oral doses of 30 mg/m(2)) plus intravenous Mercaptopurine (MP: 1 g/m(2))
Number of subjects: 0
Study 12149204 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Methotrexate (HDMTX: intravenous 1 g/m(2)) plus intravenous Mercaptopurine (MP: 1 g/m(2))
Number of subjects: 0
Study 12149204 — intervention group
Group type: COMPARATOR
Intervention: Mercaptopurine (MP: 1 g/m(2)) alone
Number of subjects: 0
Study 12149204 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus Mercaptopurine (MTX + MP)
Number of subjects: 0
Study 12149204 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Methotrexate plus Mercaptopurine (HDMTX + MP)
Number of subjects: 0
Study 12149204 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Methotrexate plus Mercaptopurine (LDMTX + MP)
Number of subjects: 0
Study 10103141 — intervention group
Group type: COMPARATOR
Intervention: cBZr parameters measured using PET (Bmax, Kd, B/F ratios)
Number of subjects: 20
Study 10103141 — intervention group
Group type: COMPARATOR
Intervention: Anxiety scores from Spielberger's and Covi's scales
Number of subjects: 20
Study 8540791 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypermobile group
Number of subjects: 20
Study 8540791 — intervention group
Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 20
Study 2189839 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy instruction
Number of subjects: 60
Study 2189839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physiotherapy instruction)
Number of subjects: 60
Study 7361026 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT)
Number of subjects: 134
Study 7361026 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (IPF)
Number of subjects: 134
Study 30617584 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allografts (FDBAs)
Number of subjects: 13
Study 30617584 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (BCP) bone substitute
Number of subjects: 13
Study 28264922 — intervention group
Group type: EXPERIMENTAL
Intervention: RDN (Renal Denervation)
Number of subjects: 139
Study 28264922 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 139
Study 25588785 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 449
Study 25588785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 23771541 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (1/200,000, 5 ml) during nasal packing (Group A1)
Number of subjects: 62
Study 23771541 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (1/200,000, 5 ml) during nasal packing with desflurane (Group A2)
Number of subjects: 62
Study 23771541 — intervention group
Group type: COMPARATOR
Intervention: Desflurane administration (Group C)
Number of subjects: 62
Study 21358314 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil, niacin and cholestyramine therapy
Number of subjects: 143
Study 21358314 — intervention group
Group type: COMPARATOR
Intervention: lifestyle intervention and placebo
Number of subjects: 143
Study 21358314 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle intervention and pharmacologic therapy
Number of subjects: 143
Study 19587364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS)
Number of subjects: 0
Study 19587364 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study 19587364 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 19587364 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 0
Study 19587364 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater insulin secretion
Number of subjects: 0
Study 19587364 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline fasting glucose
Number of subjects: 0
Study 19587364 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline 2-h glucose
Number of subjects: 0
Study 19587364 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 0
Study 19587364 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity
Number of subjects: 0
Study 19587364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS) and metformin
Number of subjects: 0
Study 19587364 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex and insulin sensitivity
Number of subjects: 0
Study 17768286 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-2-1 Go! intervention (Planet Health obesity prevention curriculum plus School Health Index for Physical Activity and Healthy Eating) implemented during 2 school years (November 2002 - May 2004)
Number of subjects: 749
Study 17768286 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 749
Study 17160917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (decreased caloric intake and increased physical activity)
Number of subjects: 5145
Study 17160917 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes support and education
Number of subjects: 5145
Study 14573726 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppb sulphur dioxide (SO2)
Number of subjects: 0
Study 14573726 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg/m3 and 2000 microg/m3 aerosols of ammonium bisulphate (AB)
Number of subjects: 0
Study 14573726 — intervention group
Group type: COMPARATOR
Intervention: Air exposure (control)
Number of subjects: 0
Study 14573726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal lavage fluid ascorbic acid (AA)
Number of subjects: 0
Study 14573726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal lavage fluid uric acid (UA)
Number of subjects: 0
Study 10582932 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at home
Number of subjects: 229
Study 10582932 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 229
Study 10582932 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at home (admitted patients)
Number of subjects: 229
Study 8934214 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 mg bid)
Number of subjects: 18
Study 8934214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (5 mg bid)
Number of subjects: 18
Study 8934214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8934214 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, Nitrendipine, Placebo
Number of subjects: 18
Study 1877056 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator without an arterial line filter (Group I)
Number of subjects: 66
Study 1877056 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator with a depth adsorption filter (Group II)
Number of subjects: 66
Study 1877056 — intervention group
Group type: COMPARATOR
Intervention: Membrane oxygenator without a filter (Group III)
Number of subjects: 66
Study 6416701 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/30 ml Adriamycin
Number of subjects: 575
Study 6416701 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/40 ml Adriamycin
Number of subjects: 575
Study 6416701 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/40 ml mitomycin C
Number of subjects: 575
Study 6416701 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 575
Study 31230933 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 0
Study 31230933 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 0
Study 27379829 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily combination of vitamin D3 (1200 IU), folic acid (0.5 mg), vitamin B12 (0.5 mg), vitamin B6 (50 mg), and calcium carbonate (456 mg) (group A)
Number of subjects: 65
Study 27379829 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 and calcium carbonate alone (group B)
Number of subjects: 65
Study 24629690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HD)
Number of subjects: 30
Study 24629690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet plus moderate aerobic exercise (HDE)
Number of subjects: 30
Study 24629690 — intervention group
Group type: EXPERIMENTAL
Intervention: HDE plus antioxidants (HDEA)
Number of subjects: 30
Study 24629690 — intervention group
Group type: COMPARATOR
Intervention: Normal weight subjects (control group)
Number of subjects: 30
Study 23153006 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (GIS) applied to permanent molars
Number of subjects: 80
Study 23153006 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (FV) applied to permanent molars
Number of subjects: 80
Study 23153006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GIS and FV
Number of subjects: 80
Study 23153006 — intervention group
Group type: EXPERIMENTAL
Intervention: GIS
Number of subjects: 80
Study 22217987 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 200 mg orally daily for 4 days, then 200 mg once weekly for 6 months
Number of subjects: 82
Study 22217987 — intervention group
Group type: EXPERIMENTAL
Intervention: K-712, 1 tablet twice a day for 4 weeks and then for the first 2 weeks of each month for a total of 6 months
Number of subjects: 82
Study 22217987 — intervention group
Group type: EXPERIMENTAL
Intervention: K-712
Number of subjects: 82
Study 22217987 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 82
Study 19727232 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory integrative training (AIT)
Number of subjects: 81
Study 19727232 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 81